HEPTA Medical

HEPTA Medical is a private French medical device company developing a minimally invasive microwave ablation platform for the treatment of early-stage lung cancer. Its core technology combines an in-situ tissue temperature sensor with proprietary predictive software to provide real-time monitoring and control of ablation procedures. The company is focused on improving precision and safety in bronchoscopic or percutaneous thermal ablation, with the goal of treating pulmonary nodules without surgery or radiation. Founded out of Sofinnova Partners' MD Start medtech acceleration platform, HEPTA raised a €5.7 million Series A round in September 2024 to support U.S. regulatory activities and the start of clinical operations. The company appears to be advancing its first device toward regulatory clearance and initial clinical development.